AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to take care of PBA AVANIR Pharmaceuticals, Inc. U drug information .S. Patent number 7 7,659,282 titled Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders was released on February 9, 2010. The new patent shall offer AVANIR with patent protection for low-dosage quinidine formulations of Zenvia used to take care of pseudobulbar affect .S. Patent was a substantial milestone for the Company and greatly enhances the intellectual property profile of Zenvia which include patents and patent applications that claim ways of treating PBA, chronic pain, as well as other neurologic circumstances.S.
The donation will help Camp Quality in its function to build resilience in the lives of kids coping with cancer and their own families, through a combined mix of fun therapy, education and medical support. Related StoriesCrucial modification in single DNA bottom predisposes children to intense type of cancerNew findings reveal association between colorectal malignancy and melanoma medication treatmentViralytics enters into scientific trial collaboration contract with MSD’We’re thrilled in order to help such a worthy cause as Camp Quality,’ stated Fred Girouard, AT&T handling director for Australia and New Zealand.